| Identification | Back Directory | [Name]
STF-118804 | [CAS]
894187-61-2 | [Synonyms]
CS-1510
STF-118804
AGN-PC-0329XY
AKOS001906141
MCULE-5035356713
AGN-PC-0329XY; AKOS001906141; MCULE-5035356713; STF-118804
STF-118804, AGN-PC-0329XY, AKOS001906141, MCULE-5035356713
4-(5-methyl-4-((phenylsulfonyl)methyl)oxazol-2-yl)-N-(pyridin-3-ylmethyl)benzamide
4-[5-Methyl-4-[[(4-methylphenyl)sulfonyl]methyl]-2-oxazolyl]-N-(3-pyridinylmethyl)benzamide
Benzamide, 4-[5-methyl-4-[[(4-methylphenyl)sulfonyl]methyl]-2-oxazolyl]-N-(3-pyridinylmethyl)-
4-[5-methyl-4-[(4-methylphenyl)sulfonylmethyl]-1,3-oxazol-2-yl]-N-(pyridin-3-ylmethyl)benzamide | [Molecular Formula]
C25H23N3O4S | [MDL Number]
MFCD14918065 | [MOL File]
894187-61-2.mol | [Molecular Weight]
461.53 |
| Chemical Properties | Back Directory | [Melting point ]
187-190°C | [density ]
1.281±0.06 g/cm3(Predicted) | [storage temp. ]
Refrigerator | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
13.00±0.46(Predicted) | [color ]
White to Off-White | [InChI]
1S/C25H23N3O4S/c1-17-5-11-22(12-6-17)33(30,31)16-23-18(2)32-25(28-23)21-9-7-20(8-10-21)24(29)27-15-19-4-3-13-26-14-19/h3-14H,15-16H2,1-2H3,(H,27,29) | [InChIKey]
DLFCEZOMHBPDGI-UHFFFAOYSA-N | [SMILES]
O=C(C1=CC=C(C2=NC(CS(=O)(C3=CC=C(C)C=C3)=O)=C(C)O2)C=C1)NCC4=CN=CC=C4 |
| Hazard Information | Back Directory | [Uses]
STF-118804 is a highly specific NAMPT inhibitor, improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia, and targets leukemia stem cells. | [Biological Activity]
STF-118804 displays pancreatic ductal adenocarcinoma (PDAC) growth reducing potential in combination with chemotherapeutic drugs.''STF-118804 is a highly specific and potent NAMPT (nicotinamide phosphoribosyl transferase) inhibitor th at reduces the viability of most B-ALL cell lines. STF 118804 induces leukemia cell apoptosis including leukemia initiating (stem) cells. STF 118804 improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia. | [in vivo]
STF-118804 (25 mg/kg, i.p., 3 weeks) demonstrates antitumor activity in an orthotopic mouse model of PDAC (Panc-1)[1].
STF-118804 (50 mg/kg, s.c., 20 days) improves survival in an orthotopic xenotransplant mouse model of high-risk acute lymphoblastic leukemia[2].
| Animal Model: | Nude mice (gender not specified, age 4 - 6 weeks) inoculated with Panc-1 cells expressing GFP-luciferase to establish an orthotopic pancreatic cancer model[1] | | Dosage: | 25 mg/kg | | Administration: | Intraperitoneal injection (i.p.), 3 weeks | | Result: | Reduced tumor growth as demonstrated by decreased luminescence, tumor weight and size.
Had no significant toxicity.
|
| [storage]
Store at -20°C |
|
|